Assessment of The Efficacy of Intratympanic Platelet Rich Plasma for Treatment of Sensorineural Hearing Loss.

Assiut University

Status and phase: Not yet enrolling; Phase 3; Phase 2

Conditions: Hearing Loss, Sudden; Hearing Loss; Hearing Loss, Sensorineural

Treatments: Procedure: Intratympanic Injection; Drug: local anesthesia in external auditory canal; Biological: Platelet Rich Plasma

Study type: Interventional

Funder types: Other

Identifiers

NCT05786378

Intratympanic PRP

Details and patient eligibility

About

Assessment of the efficacy of Intratympanic platelet rich plasma injection for treatment of idiopathic suden sensorineural hearing loss

Full description

Sensorineural hearing loss is the collective term for hearing damage to the cochlea and auditory nerve and is by far the most common type of hearing loss in adults, accounting for over 90% of all cases. Sensorineural hearing loss is a heterogeneous disorder, which can arise due to damage to pathway for sound impulses from the hair cells of inner ear to auditory nerve and less commonly brain.

Sensorineural hearing loss is a challenge to physicians, as it progresses with age and causes significant reductions in quality of life and there are no treatments to reverse its effects, other than sound amplification with the use of hearing aids or direct auditory nerve stimulation via cochlear implantation.

Platelet-rich Plasma (PRP) Therapy is a cutting-edge procedure that is revolutionizing the hearing loss and deafness. Intratympanic instillation of Platelet-rich Plasma (PRP) does wonder to the hair cells of inner ear, thus improving the hearing.

Enrollment: 23 estimated patients

Sex: All

Ages: 5 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients have sudden idiopathic sensorineural hearing loss

Exclusion criteria

1. patients has previous ear surgery.
2. patients has absent cochlea in CT or MRI
3. patients has Cancer,Chronic liver disease, Hemodynamic instability,Hypofibrinogenemia, Platelet dysfunction syndromes, Systemic disorder, sepsis, Low platelet count.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

23 participants in 1 patient group

platlet rich plasma

Experimental group

Treatment:

Procedure: Intratympanic Injection

Biological: Platelet Rich Plasma

Drug: local anesthesia in external auditory canal